Zobrazeno 1 - 10
of 518
pro vyhledávání: '"Yongping SONG"'
Identification of potential immune-related mechanisms related to the development of multiple myeloma
Autor:
Yaomei Wang, Wenli Zhang, Tiandong Li, Mengmeng Liu, Mengya Gao, Xinqing Li, Yufei Chen, Yongping Song, Wei Li, Chunyan Du, Fang Wang, Lina Liu, Sihan Zhou, Xiuyuan Hao
Publikováno v:
Chinese Medical Journal, Vol 137, Iss 13, Pp 1603-1613 (2024)
Abstract. Background:. Although significant advances have been made in the treatment of multiple myeloma (MM), leading to unprecedented response and survival rates among patients, the majority eventually relapse, and a cure remains elusive. This situ
Externí odkaz:
https://doaj.org/article/d33f19cce9f14844801e95cf1e3f9bad
Autor:
Yingling Zu, Huifang Zhao, Jianling Chen, Huibing Dang, Yanrong Shi, Lixin Liang, Shuhao Mei, Yongping Song, Yanli Zhang
Publikováno v:
Journal of Hematology & Oncology, Vol 17, Iss 1, Pp 1-3 (2024)
Abstract Unintended pregnancy for female patients with chronic myeloid leukemia (CML) raises the discussion of treatment choices due to the teratogenicity of tyrosine kinase inhibitor (TKI). We report 51 accidental pregnant CML chronic phase (CP) pat
Externí odkaz:
https://doaj.org/article/887b412888ba496abb37888ec19c5403
Publikováno v:
Chinese Medical Journal, Vol 137, Iss 11, Pp 1285-1302 (2024)
Abstract. The advent of chimeric antigen receptor (CAR)-T cell immunotherapies has led to breakthroughs in the treatment of hematological malignancies. However, their success in treating solid tumors has been limited. CAR-natural killer (NK) cells ha
Externí odkaz:
https://doaj.org/article/abee27cb29594a5f9a025fa68686c444
Autor:
Tongcheng Dai, Hao Sun, Tyler Liban, Ildefonso Vicente-Suarez, Bin Zhang, Yongping Song, Zhongxing Jiang, Jifeng Yu, Jackie Sheng, Binhua Lv
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-15 (2024)
Abstract We report the generation of a novel anti-LAG-3/TIGIT bispecific IgG4 antibody, ZGGS15, and evaluated its anti-tumor efficacy in mouse models as monotherapy or in combination with a PD-1 antibody. ZGGS15 exhibited strong affinities for human
Externí odkaz:
https://doaj.org/article/0562a51f66094c5ca19d04378fc77382
Publikováno v:
Chinese Medical Journal, Vol 137, Iss 7, Pp 776-790 (2024)
Abstract. B-cell lymphoma is a group of hematological malignancies characterized by variable genetic and biological features and clinical behaviors. The tumor microenvironment (TME) is a complex network in tumors, which consists of surrounding blood
Externí odkaz:
https://doaj.org/article/6123cc5d370545d3957f75ac63f6849e
Publikováno v:
Genes and Diseases, Vol 11, Iss 5, Pp 101150- (2024)
The advent of tyrosine kinase inhibitors (TKI) targeting BCR-ABL has drastically changed the treatment approach of chronic myeloid leukemia (CML), greatly prolonged the life of CML patients, and improved their prognosis. However, TKI resistance is st
Externí odkaz:
https://doaj.org/article/7cfec49cead04316911cebf15dc34f7c
Autor:
Yuankai Shi, Keshu Zhou, Hui Zhou, Yan Qin, Hongmei Jing, Ying Xiang, Zhao Wang, Zhen Wang, Aimin Zang, Ou Bai, Zhenyu Li, Huilai Zhang, Yongping Song, Jinjin Liang, Min Wei
Publikováno v:
EClinicalMedicine, Vol 73, Iss , Pp 102702- (2024)
Summary: Background: MIL62, a novel glycoengineered type Ⅱ anti-CD20 monoclonal antibody, with a nearly completely afucosylated N-glycans in Fc region, has demonstrated superior activity compared with rituximab and obinutuzumab in vitro and in vivo
Externí odkaz:
https://doaj.org/article/2a3c6df3d77e4c00af3f193cded6e60d
Autor:
Zhishu Jiang, Xin Wang, Zhiwei Zhou, Limei Peng, Xiaoli Lin, Xiaowei Luo, Yongping Song, Huaying Ning, Cong Gan, Xiaopeng He, Changlan Zhu, Linjuan Ouyang, Dahu Zhou, Yicong Cai, Jie Xu, Haohua He, Yantong Liu
Publikováno v:
BMC Plant Biology, Vol 24, Iss 1, Pp 1-16 (2024)
Abstract Background D-type cyclins (CYCD) regulate the cell cycle G1/S transition and are thus closely involved in cell cycle progression. However, little is known about their functions in rice. Results We identified 14 CYCD genes in the rice genome
Externí odkaz:
https://doaj.org/article/74433cef22474e8c8f0fa9cf851d128a
Publikováno v:
Experimental Hematology & Oncology, Vol 13, Iss 1, Pp 1-4 (2024)
Abstract Over the past few years, dual-targeted chimeric antigen receptor (CAR) T-cell therapy has been employed in the management of hematological malignancies to mitigate treatment failure, particularly in cases of antigen escape. The most widely u
Externí odkaz:
https://doaj.org/article/4751ec16a45d402d9601992b5e44c432
Autor:
Yan Qin, Yongping Song, Dong Wang, Ou Bai, Jifeng Feng, Xiuhua Sun, Lihua Qiu, Jianmin Yang, Yu Yang, Zhao Wang, Jianda Hu, Huaqing Wang, Hang Su, Zhengming Jin, Wenbin Qian, Chuan Jin, Mingzhi Zhang, Ding Yu, Li Liu, Guoan Chen, Yarong Li, Tao Sun, Jie Jin, Huizheng Bao, Xin Du, Hui Zhou, Gan Fu, Yuankai Shi
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract HLX01 (HanliKang®) is a rituximab biosimilar that showed bioequivalence to reference rituximab in untreated CD20-positive diffuse large B-cell lymphoma (DLBCL) in the phase 3 HLX01-NHL03 study. Here, we report the 5-year follow-up results f
Externí odkaz:
https://doaj.org/article/7eecafad55844bb3b801aa99db2e8a55